Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
0.45
Industry P/E
--
Debt to Equity
0
ROE
-1.81 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-5.39
CFO
$-124.79 Mln
EBITDA
$-183.84 Mln
Net Profit
$-149.84 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Matinas Biopharma Holdings (MTNB)
| 23.45 | 11.43 | 0.27 | -92.96 | -73.54 | -55.37 | -36.05 |
|
BSE Sensex*
| 2.76 | 3.86 | 5.93 | 9.05 | 11.81 | 20.15 | 11.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Matinas Biopharma Holdings (MTNB)
| -95.16 | -56.80 | -50.50 | -25.74 | -40.09 | 281.51 | -48.52 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.68 | 78.84 | -- | -62.96 | |
| 8.54 | 801.08 | -- | -69.5 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 25.94 | 2,881.32 | -- | -14.59 |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid... nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey. Address: 1545 Route 206 South, Bedminster, NJ, United States, 07921 Read more
Co-Founder, CEO, President & Director
Mr. Jerome D. Jabbour J.D.
Chief Financial Officer
Mr. Keith A. Kucinski CPA, M.B.A.
Headquarters
Bedminster, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Matinas Biopharma Holdings Inc (MTNB) stood at $ 21 Mln as on 31-Mar-25
The share price of Matinas Biopharma Holdings Inc (MTNB) is $0.63 (NYSE) as of 28-Apr-2025 16:10 EDT. Matinas Biopharma Holdings Inc (MTNB) has given a return of -73.54% in the last 3 years.
Matinas Biopharma Holdings Inc (MTNB) has a market capitalisation of $ 3 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Matinas Biopharma Holdings Inc (MTNB) is 0.45 times as on 28-Apr-2025, a 80% discount to its peers’ median range of 2.29 times.
Since, TTM earnings of Matinas Biopharma Holdings Inc (MTNB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Matinas Biopharma Holdings Inc (MTNB) and enter the required number of quantities and click on buy to purchase the shares of Matinas Biopharma Holdings Inc (MTNB).
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey. Address: 1545 Route 206 South, Bedminster, NJ, United States, 07921
The CEO & director of Mr. Jerome D. Jabbour J.D.. is Matinas Biopharma Holdings Inc (MTNB), and CFO & Sr. VP is Mr. Keith A. Kucinski CPA, M.B.A..
There is no promoter pledging in Matinas Biopharma Holdings Inc (MTNB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
867
|
|
|
290
|
|
|
80
|
|
|
8
|
| Matinas Biopharma Holdings Inc. (MTNB) | Ratios |
|---|---|
|
Return on equity(%)
|
-229.88
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Matinas Biopharma Holdings Inc (MTNB) was $0 Mln.
$-0.04
(
